AAOpt 2025: A real-world assessment of dry eye relief in habitual drop users | Optometry Times - Clinical News

The FDA Adverse Event Reporting System was used to find five drug candidates with the highest underrecognized maculopathy risk—fingolimod, apixaban, paclitaxel, ibrutinib and sildenafil. However, cumulative incidence rates were high among four of these candidates—apixaban, paclitaxel, ibrutinib and sildenafil—meaning they should be evaluated further for maculopathy both in practice and in clinical